Insight Molecular Diagnostics Inc. (IMDX) · Nov 18, 2026 · Share issuance
$15M equity financing — 8.57M shares equivalent at $1.75; 15% over-allotment option
Insight Molecular Diagnostics priced a $15M stock offering to fund its FDA-stage transplant diagnostics business, extending cash but increasing dilution.
iMDx is a pre-commercial transplant-diagnostics company trying to move GraftAssureDx from FDA review into a clinical product launch; its existing business is still small, with Q3 revenue of $559,000, while the company reported $11.8 million of cash and restricted cash and roughly $7.3 million of negative free cash flow for the quarter.
The financing removes an immediate funding constraint. The company is raising approximately $15.0 million gross for working capital and general corporate purposes, a meaningful capital injection against its recent cash burn.
The cost is substantial equity dilution rather than business progress. Investors are buying 8.296 million shares plus pre-funded warrants for another 275,000 shares at effectively the same $1.75 price, with a further 1.286 million shares available through the underwriter’s option.
| Offering detail | Amount | Comparison |
|---|---|---|
| Common shares offered (Underwriting Agreement) | 8,296,429 | |
| Pre-funded warrant shares (Underwriting Agreement) | 275,000 | |
| Gross proceeds (Offering) | $15.0M | |
| Offering price (Press release) | $1.75 | |
| Underwriter option (Underwriting Agreement) | 1,285,714 shares | 30 days |
The timing underscores that FDA execution remains the value-creating milestone. The financing arrives while GraftAssureDx remains under FDA review and before the company’s January 21, 2027 deadline to answer the agency’s additional-information request; the proceeds fund the bridge to that decision but do not reduce the regulatory risk itself.
Bottom line: This strengthens iMDx’s ability to keep operating through the FDA process, but it is a financing rescue rather than a commercial or regulatory win. The business story is modestly improved on liquidity and weakened by fresh dilution and continued dependence on capital markets.
Complete FDA response to GraftAssureDx request, due January 21, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!